Phase 4 N=161 Utility of Trimethoprim-sulfamethoxazole Use in Skin Abscess Management
Skin Diseases, Infectious
Primary: Skin Abscess Resolution — 4; 3 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=23 Management of Skin and Soft Tissue Abscesses in Pediatric Patients After Incision and Drainage
Abscess
Primary: Number of Participants With Abscess Resolution — 11; 9 Participants
N/A N=31 Trial of Antibiotic Treatment for Skin Abscess in Patients at Risk for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection
Abscess
Primary: Clinical Improvement at 7 Days After Incision and Drainage — 10; 14 participants
Phase 2 N=6 Safety and Tolerability Study of Antimicrobial TheraGauze for Skin Abscess
Furunculosis
Primary: Number of Side-effects — 4; 2 Participants
N/A N=139 Trial of Septra for Uncomplicated Skin Abscesses in Patients at Risk for Community Acquired Methicillin-Resistant Staphylococcus Aureus Infection
Abscess · Methicillin-Resistant Staphylococcus Aureus Infection
Primary: Recurrence Rates of Abscesses — 4; 14 participants
Phase 2 N=92 Aquacel Versus Iodoform Gauze for Filling Abscess Cavity Following Incision and Drainage
Abscess · Cellulitis
Primary: Number of Participants Who Experienced a 30% or Greater Reduction in Surface Area of Abscess — 6; 19 Participants — p=.0003
Phase 3 N=212 Prospective Randomized Trial of Bactrim on 7 Day Outcome in Patients With Uncomplicated Abscesses
Abscesses
Primary: Treatment Failures at 7 Days — 15; 27 participants
N/A N=265 Evaluation of 3 Versus 10 Days of Antibiotics in Skin Abscesses After Surgical Drainage
Skin Disease, Bacterial · Abscess
Primary: Treatment Failures — 9; 4 participants — p=0.25
Phase 4 N=50 Evaluation of a Staphylococcus Eradication Protocol for Patients Who Present to the ED With Cutaneous Abscess
Cutaneous Abscess
Primary: Recurrence of Cutaneous Abscess — 5; 7 Participants
Phase 2 N=1,310 Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus
Staphylococcal Infection
Primary: Percentage of Participants Achieving Clinical Cure, Defined as Absence of Clinical Failure, in the Evaluable Population. — 89.5; 88.2; 92.9; 92.7 percentage of…
Phase 2 N=20 Alteplase for Percutaneous Treatment of Loculated Abdominopelvic Abscesses
Abdominal Abscess · Pelvic Abscess
Primary: Percentage of Patients Requiring Surgical Debridement for a Persistent Abscess Within 30 Days Following Initial Drainage — 3; 7 participants
Phase 4 N=40 Comparison of Excision Versus Punch Incision in the Treatment of Epidermal Cysts
Epidermal Cyst
Primary: Number of Participants With Cyst Recurrence — 3; 2 participants
Phase 2 N=200 A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study
Major Cutaneous Abscess · Cellulitis · Erysipelas
Primary: Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) — 91 participants
Phase 2 N=20 Phase 2a Study of CG400549 for the Treatment of cABSSSI Caused by Methicillin-resistant Staphylococcus Aureus
Skin Infection
Primary: Status of Subject's Clinical Responses — 10; 1 participants
N/A N=15 Hidradenitis Suppurativa (HS) Tunneling Wounds
Hidradenitis Suppurativa
Primary: Change in Microbiome — 5.46; 3.88 colony forming units per ml (CFU/ml)
Phase 2 N=120 TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection
Skin and Subcutaneous Tissue Bacterial Infections · Gram-Positive Bacterial Infections
Primary: Early Clinical Response at the Early Assessment (EA) Visit in the Intent-to-Treat (ITT) Population — 61; 27; 4; 3 Participants
N/A N=420 Emergency Bedside Ultrasound for Pediatric Soft Tissue Infections
Abscess
Primary: Sensitivity and Specificity of Bedside Emergency Ultrasound When Added to the Clinical Examination Compared With Clinical Examination Alone. — 94.7; 93.1; 84.2; 81.4…
Phase 2 N=12 Topical Treatment and Prevalence of P. Acnes
Surgical Site Infection
Primary: Number of Subjects With Positive Bacterial Growth Culture Per Treatment Arms — 10; 12; 10; 10 participants
Phase 2 N=330 Study of Debio 1450 for Bacterial Skin Infections
Bacterial Infections
Primary: Early Clinical Response Rate (ECRR): Percentage of Responders to Treatment at 48 to 72 Hours From Randomization as Assessed by the Investigator — 94.6; 90.1; 91.1…
Phase 2 N=256 A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections
Skin and Subcutaneous Tissue Bacterial Infections
Primary: Investigator's Assessment of Clinical Response in the ITT (Intent-to-treat) Population at Follow-up — 57; 50; 53 Participants
Phase 4 N=100 Evaluation of Daptomycin for the Emergency Department Treatment of Complicated Skin and Skin Structure Infections
Cellulitis · Skin Infections
Primary: Satisfaction of Discharge Criteria — 15; 14 participants
Phase 2 N=122 Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Infections, Bacterial
Primary: Number of Participants With Composite of the Cure Rate as Measured by Clinical Response and Outcome at the Early Efficacy Visit Combined With Withdrawal Rate — 48; 28…
Phase 3 N=660 Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Skin and Subcutaneous Tissue Bacterial Infections
Primary: Objective Response at 48 to 72 Hours (FDA Primary Endpoint) — 259; 266; 72; 63 Participants
Phase 4 N=200 Comparison of Cephalexin Versus Clindamycin for Suspected CA-MRSA Skin Infections
Staphylococcal Infection · Abscess · Staphylococcal Skin Infection
Primary: Clinical Improvement at the 48-72 Hour Clinical Follow-up — 94; 97 participants
Phase 3 N=679 Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections
Acute Bacterial Skin and Skin Structure Infections
Primary: Early Clinical Response — 306; 303 Participants
N/A N=25 Daptomycin for the Treatment of Severe Necrotizing Soft-Tissue Infections
Fasciitis, Necrotizing · Severe Necrotizing Skin and Soft Tissue Infections · Fournier's Gangrene
Primary: Clinical Response to High Dose Daptomycin Therapy at End of Treatment (EOT) — 16; 0; 2; 0 Participants
Phase 2 N=84 GSK1322322 Versus Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infection
Skin Infections, Bacterial
Primary: Number of Participants With Any Adverse Events (AE) and Serious Adverse Events (SAE) — 49; 20; 1; 1 Participants
Phase 3 N=655 Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23)
Bacterial Infections · Skin Structures and Soft Tissue Infections
Primary: Number of Participants With Early Clinical Response — 268; 266; 23; 19 Participants
Phase 4 N=91 Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Bacterial Infections · Acute Bacterial Skin and Skin Structure Infection
Primary: Number of Infection-related Total Admitted Hospital Days — 4.8; 3.2 Days — p=0.003
N/A N=80 Skin Prep to Reduce Postoperative Shoulder Infection
Shoulder Infection
Primary: Skin Swab and Culture With Colony Forming Units (CFUs) — 39; 51; 35; 22 negative skin cultures — p=0.68